Hypera S.A. (OTCPK:HYPMY) Q4 2023 Earnings Conference Call March 21, 2025 10:00 AM ET
Company Participants
Breno Toledo Pires de Oliveira – Chief Executive Officer
Adalmario Ghovatto Satheler do Couto – Investor Relations Officer
Ramon Sanches Frutuoso Silva – Chief Financial Officer
Conference Call Participants
Joseph Giordano – JP Morgan
Robert Ford – Bank of America
Mauricio Cepeda – Morgan Stanley
Vinicius Figueiredo – Itau BBA
Samuel Alves – BTG Pactual
Operator
Good morning, ladies and gentlemen. Welcome to Hypera Pharma’s Earnings Call for the Fourth Quarter of 2024. We have with us Mr. Breno Oliveira, CEO; Ramon Silva, CFO; and Adalmario Couto, IRO.
This event is being recorded. The video can be seen at the company’s Investor Relations website, ri.hypera.com.br. We would also like to inform you that all participants will be in listen-only mode. We will then have a Q&A session. Further instructions will be given at this time.
Before we proceed, I would like to reinforce that some information in this conference call may contain projections or statements about future expectations. This information is subject to known and unknown risks and uncertainties that may cause them not to materialize or to be substantially different from what was expected.
I will now turn it over to Mr. Breno Oliveira who will begin the presentation. Mr. Oliveira, you have the floor.
Breno Toledo Pires de Oliveira
Good morning. I’d like to thank you all for being here for our earnings presentation. I will start speaking about our growth on Slide 3. Our sell-out went up 9% in 2024. In the institutional non-retail market it was 26% and in the retail market, it was 8%. We are continuing to grow significantly in the non-retail market. It was nearly 20 percentage points above the overall market growth. This was mainly driven by acceleration in sales for our current portfolio.
